menu
    • menu
    [{"orgOrder":0,"company":"Alchemab","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Alchemab","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alchemab \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Alchemab \/ Eli Lilly"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Mina Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mina Therapeutics \/ Servier","highestDevelopmentStatusID":"3","companyTruncated":"Mina Therapeutics \/ Servier"},{"orgOrder":0,"company":"Alchemab","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Alchemab","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alchemab \/ RA Capital Management","highestDevelopmentStatusID":"3","companyTruncated":"Alchemab \/ RA Capital Management"},{"orgOrder":0,"company":"Alchemab","sponsor":"Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Alchemab","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Alchemab \/ Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"3","companyTruncated":"Alchemab \/ Michael J. Fox Foundation for Parkinson\u2019s Research"},{"orgOrder":0,"company":"Bit Bio","sponsor":"Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Bit Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Bit Bio \/ Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"3","companyTruncated":"Bit Bio \/ Michael J. Fox Foundation for Parkinson\u2019s Research"},{"orgOrder":0,"company":"Wren Therapeutics","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Alpha-synuclein aggregation","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Wren Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Wren Therapeutics \/ Eisai","highestDevelopmentStatusID":"3","companyTruncated":"Wren Therapeutics \/ Eisai"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alchemab

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed

                            Alchemab

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Alchemab, Lilly Partner to Develop ALS Drug Candidates

                            Details : Alchemab will collaborate with Lilly to discover, develop and commercialise antibodies for the treatment of amyotrophic lateral sclerosis.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            January 09, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alchemab

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed

                            Alchemab

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery Platform

                            Sponsor : Michael J. Fox Foundation for Parkinson’s Research

                            Deal Size : $0.5 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Alchemab Advances Novel Antibody for Parkinson's Disease with Michael J. Fox Foundation

                            Details : The grant will fund research performed at Alchemab following its identification of antibodies that target prostaglandin biology in Parkinson's disease (PD), a potentially unique approach to treatment.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 06, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery Platform

                            Sponsor : Michael J. Fox Foundation for Parkinson’s Research

                            Deal Size : $0.5 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Bit Bio

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed

                            Bit Bio

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery Platform

                            Sponsor : Michael J. Fox Foundation for Parkinson’s Research

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Bit.Bio Announces First Project with The Michael J. Fox Foundation for Parkinson’s

                            Details : The collaboration with MJFF leverages bit.bio’s discovery platform and opti-ox technology for reprogramming iPSCs into functional human cells for research in Parkinson’s disease.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 03, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery Platform

                            Sponsor : Michael J. Fox Foundation for Parkinson’s Research

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Alchemab

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed

                            Alchemab

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery Platform

                            Sponsor : RA Capital Management

                            Deal Size : $82.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Alchemab Completes £60m Series A funding To Advance Novel Antibody Platform

                            Details : The funding will be used to advance Alchemab’s novel platform, designed to identify disease-modifying antibody therapeutics.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            April 15, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery Platform

                            Sponsor : RA Capital Management

                            Deal Size : $82.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Mina Therapeutics

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed

                            Mina Therapeutics

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery Platform

                            Sponsor : Servier

                            Deal Size : $262.2 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Servier and MiNA Therapeutics Enter Collaboration in Neurological Diseases

                            Details : As part of the collaboration, MiNA Therapeutics will use its saRNA platform to identify new potential treatments to restore normal cell function in neurological disorders.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            January 21, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery Platform

                            Sponsor : Servier

                            Deal Size : $262.2 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Wren Therapeutics

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed

                            Wren Therapeutics

                            United Kingdom arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery Platform

                            Sponsor : Eisai

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Eisai and Wren Therapeutics Enter Into Research Collaboration Agreement for Drug Discovery for Synucleinopathi...

                            Details : The collaboration will use Wren’s network kinetics drug discovery platform, alongside Eisai’s extensive experience in drug discovery for neurodegenerative disorders, to accelerate the development of clinical candidates.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 30, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery Platform

                            Sponsor : Eisai

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth